三阴性乳腺癌免疫治疗的研究进展  

Research Progress on Immunotherapy in Triple-Negative Breast Cancer

作　　者：马萍 陈丽[1] 赵远 唐文如[1] 盛苗苗 MA Ping;CHEN Li;ZHAO Yuan;TANG Wenru;SHENG Miaomiao(Laboratory of Molecular Genetics of Aging&Tumor,Kunming University of Science and Technology,Kunming 650500,China)

机构地区：[1]昆明理工大学,衰老与肿瘤分子遗传学实验室,昆明650500

出　　处：《中国细胞生物学学报》2020年第10期1835-1842,共8页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:81560451)资助的课题。

摘　　要：三阴性乳腺癌是一种雌激素受体、孕激素受体阴性和人表皮生长因子受体-2低表达的乳腺癌。与其他亚型的乳腺癌相比,三阴性乳腺癌具有侵袭潜能强、复发率高、预后较差等特点,是乳腺癌中最棘手的一种类型,目前其在临床上缺少有效的治疗方案。免疫治疗作为一种新的临床治疗方法,对三阴性乳腺癌的治疗具有重要的临床意义,为患者提供了新的治疗选择。该文就近年来三阴性乳腺癌免疫治疗的研究进展作一综述,主要内容包括三阴性乳腺癌的分子分类、主动免疫治疗、被动免疫治疗、溶瘤免疫治疗以及免疫治疗的前景。Triple-negative breast cancer is a kind of breast cancer with negative estrogen receptor and progesterone receptor,and low expression of human epidermal growth factor receptor-2.Compared with other subtypes of breast cancer,triple-negative breast cancer has the characteristics of strong invasive potential,high recurrence rate and poor prognosis.It is one of the most intractable types of breast cancer.At present,there is a lack of effective treatment.As a new clinical treatment,immunotherapy has great clinical significance for the treatment of triple-negative breast cancer,and provides new treatment options for patients.The present article reviews the research progresses of immunotherapy for triple-negative breast cancer in recent years.The main contents cover the molecular classification,active immunotherapy,passive immunotherapy,oncolytic immunotherapy,and the prospect of immunotherapy for triple-negative breast cancer.

关 键 词：三阴性乳腺癌 免疫治疗 免疫检查点抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]